New Regimen for Localized Gastric Cancers Presented at ASCO

Adding the immunotherapy Imfinzi to standard chemotherapy improves outcomes for people with resectable gastric or gastroesophageal junction cancer, per results presented at the 2025 ASCO Annual Meeting.